Core Viewpoint - CRISPR Therapeutics, despite a 24% decline in share price since mid-2022, has potential for significant returns due to its innovative gene-editing therapies, particularly with its first approved product, Casgevy [1][2]. Group 1: Product Development and Market Potential - CRISPR Therapeutics' first approved product, Casgevy, treats sickle cell disease and transfusion-dependent beta-thalassemia, marking a milestone as the first CRISPR-based gene-editing medicine approved [3]. - The treatment faces challenges, including a complex manufacturing process and a high cost of $2.2 million in the U.S., making reimbursement from third-party payers a significant hurdle [4]. - The company has activated 75 authorized treatment centers and secured reimbursement for eligible patients in 10 countries, targeting approximately 60,000 eligible patients [6]. Group 2: Financial Projections - If CRISPR Therapeutics can secure reimbursement for 70% of the target population and treat 30% over the next decade, Casgevy could generate over $27.7 billion, with CRISPR's share estimated at $11.1 billion [7]. - While Casgevy could contribute significantly to the company's revenue, it may primarily serve as proof of concept for the effectiveness of the biotech's approach [8]. Group 3: Future Pipeline and Growth Potential - CRISPR Therapeutics has six candidates in clinical trials, including CTX310, which shows promise in reducing LDL cholesterol and is easier to handle than ex vivo therapies [10]. - The company's future success relies on achieving consistent clinical and regulatory wins for CTX310 and other candidates, which could lead to a substantial increase in share price [11]. - A successful launch of new products in the next five to seven years could make gene-editing medicines more mainstream, encouraging third-party payers and healthcare institutions to support the treatments [12].

Company Overview - Cellectis is a clinical-stage biotechnology company focused on developing life-saving cell and gene therapies using its gene-editing platform [2][3] - The company is pioneering an allogeneic approach for CAR T immunotherapies in oncology, offering off-the-shelf and ready-to-use gene-edited CAR T-cells for cancer treatment [2][3] - Cellectis has in-house manufacturing capabilities, making it one of the few end-to-end gene editing companies that control the entire cell and gene therapy value chain [2] Financial Reporting - Cellectis will report its financial results for the second quarter of 2025 on August 4, 2025, after the close of the US market [1] - An investor conference call and webcast will take place on August 5, 2025, at 8:00 AM ET, to discuss the second quarter results and provide updates on business activities [2] Contact Information - Media contacts include Pascalyne Wilson and Patricia Sosa Navarro for communications inquiries [4] - Investor relations inquiries can be directed to Arthur Stril, the Chief Financial Officer & Chief Business Officer [4]

Company Overview - Cellectis is a clinical-stage biotechnology company focused on developing life-saving cell and gene therapies using its gene-editing platform [2][3] - The company employs an allogeneic approach for CAR T immunotherapies in oncology, introducing off-the-shelf and ready-to-use gene-edited CAR T-cells for cancer treatment [2] - Cellectis has in-house manufacturing capabilities, making it one of the few end-to-end gene editing companies that manage the entire cell and gene therapy value chain [2] Upcoming Events - Cellectis will hold its annual general meeting on June 26, 2025, at 2:30 p.m. CET in Paris, France [1] - Detailed agenda and modalities for participation in the meeting are available on the Cellectis website [2]

Core Points - Cellectis, a clinical-stage biotechnology company, will hold its annual general meeting on June 26, 2025, at 2:30 p.m. CET in Paris, France [1] - The company specializes in developing life-saving cell and gene therapies using its gene-editing platform [2][3] - Cellectis employs an allogeneic approach for CAR T immunotherapies, focusing on off-the-shelf gene-edited CAR T-cells for cancer treatment [2] - The company has in-house manufacturing capabilities, making it one of the few end-to-end gene editing companies that control the entire value chain [2] Company Information - Cellectis is headquartered in Paris, France, with additional locations in New York and Raleigh, NC [3] - The company is listed on the Nasdaq Global Market (ticker: CLLS) and Euronext Growth (ticker: ALCLS) [3] - For more information, Cellectis provides contact details for media and investor relations [4]